A Phase 4 Open-label Randomized Controlled Study COmparing the Effectiveness of Adalimumab iNTROduction and Methotrexate Dose escaLation in Subjects With Psoriatic Arthritis (CONTROL)
Phase of Trial: Phase IV
Latest Information Update: 18 Aug 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- Acronyms CONTROL
- Sponsors AbbVie
- 13 Jan 2017 Planned End Date changed from 1 Jan 2019 to 1 Aug 2019.
- 24 Aug 2016 Status changed from not yet recruiting to recruiting.
- 08 Jul 2016 New trial record